Neurocrine Biosciences (NBIX)
Neurocrine Biosciences on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
6.4M
Short interest
settlement 2026-10-15
4.5
Days to cover
+0.6 days vs prior
61.7%
Short share of volume
2026-10-28
1,221
Fails to deliver
settlement 2026-09-11
Wed 10 Feb
Next earnings
estimated date
-$826K
Insider flow, 90 days
0 buys, 3 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in NBIX is 6,447,491 shares, up 1,482,584 shares over the last month. Over the last 48 readings it ranged from 2,404,128 shares (31 January 2025) to 6,447,491 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 1.4M shares a day that is 4.5 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/nbix" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 6,447,491 | +10.2% | 1,418,632 | 4.54 |
| 2026-09-30 | 5,853,128 | +17.9% | 1,476,037 | 3.97 |
| 2026-09-15 | 4,964,907 | -1.8% | 924,045 | 5.37 |
| 2026-08-31 | 5,056,144 | +11.1% | 1,086,635 | 4.65 |
| 2026-08-14 | 4,551,075 | +3.7% | 1,329,597 | 3.42 |
| 2026-07-31 | 4,390,083 | -17.7% | 1,456,278 | 3.01 |
| 2026-07-15 | 5,334,688 | -3.5% | 1,086,810 | 4.91 |
| 2026-06-30 | 5,530,854 | -2.8% | 1,315,407 | 4.20 |
| 2026-06-15 | 5,690,488 | +2.9% | 1,128,101 | 5.04 |
| 2026-05-29 | 5,529,509 | +7.2% | 1,114,763 | 4.96 |
| 2026-05-15 | 5,160,707 | -13.9% | 1,400,192 | 3.69 |
| 2026-04-30 | 5,992,527 | +6.2% | 1,163,604 | 5.15 |
| 2026-04-15 | 5,644,452 | +23.9% | 1,160,869 | 4.86 |
| 2026-03-31 | 4,557,132 | +18.1% | 982,231 | 4.64 |
| 2026-03-13 | 3,858,266 | +14.1% | 980,935 | 3.93 |
| 2026-02-27 | 3,382,324 | +7.1% | 1,025,508 | 3.30 |
| 2026-02-13 | 3,158,474 | -5.4% | 1,499,285 | 2.11 |
| 2026-01-30 | 3,340,144 | -4.6% | 925,058 | 3.61 |
| 2026-01-15 | 3,501,097 | -13.9% | 1,280,253 | 2.73 |
| 2025-12-31 | 4,067,222 | +3.3% | 997,996 | 4.08 |
| 2025-12-15 | 3,939,195 | -1.2% | 884,478 | 4.45 |
| 2025-11-28 | 3,987,908 | +18.8% | 991,030 | 4.02 |
| 2025-11-14 | 3,355,702 | -18.4% | 1,173,716 | 2.86 |
| 2025-10-31 | 4,114,577 | -5.8% | 1,026,717 | 4.01 |
| 2025-10-15 | 4,366,857 | +2.5% | 811,746 | 5.38 |
| 2025-09-30 | 4,262,521 | +3.5% | 904,194 | 4.71 |
| 2025-09-15 | 4,119,845 | -0.3% | 830,487 | 4.96 |
| 2025-08-29 | 4,130,984 | +3.7% | 615,824 | 6.71 |
| 2025-08-15 | 3,984,398 | +39.6% | 1,010,664 | 3.94 |
| 2025-07-31 | 2,853,448 | -11.8% | 1,027,016 | 2.78 |
| 2025-07-15 | 3,234,044 | -8.5% | 795,599 | 4.06 |
| 2025-06-30 | 3,534,131 | +1.1% | 880,258 | 4.01 |
| 2025-06-13 | 3,495,103 | -14.0% | 861,233 | 4.06 |
| 2025-05-30 | 4,064,860 | +0.9% | 1,081,172 | 3.76 |
| 2025-05-15 | 4,029,414 | -10.2% | 1,984,165 | 2.03 |
| 2025-04-30 | 4,485,608 | +2.6% | 1,590,320 | 2.82 |
| 2025-04-15 | 4,370,717 | +15.4% | 1,923,810 | 2.27 |
| 2025-03-31 | 3,785,885 | +14.9% | 1,102,144 | 3.44 |
| 2025-03-14 | 3,293,529 | +2.1% | 1,347,686 | 2.44 |
| 2025-02-28 | 3,225,389 | +5.9% | 1,265,375 | 2.55 |
| 2025-02-14 | 3,044,928 | +26.6% | 2,139,962 | 1.42 |
| 2025-01-31 | 2,404,128 | -24.9% | 942,290 | 2.55 |
| 2025-01-15 | 3,199,103 | -4.5% | 954,772 | 3.35 |
| 2024-12-31 | 3,349,662 | -1.1% | 1,183,443 | 2.83 |
| 2024-12-13 | 3,387,745 | -13.3% | 681,921 | 4.97 |
| 2024-11-29 | 3,909,001 | -7.8% | 1,035,182 | 3.78 |
| 2024-11-15 | 4,238,364 | +70.8% | 978,467 | 4.33 |
| 2024-10-31 | 2,480,887 | -5.3% | 976,264 | 2.54 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of NBIX volume is 61.7%, down 4.6 points over the last five sessions. Over the last 30 readings it ranged from 41.3% (25 September 2026) to 81.0% (23 October 2026). The latest reading is 2.7 points below the 30-session average of 64.4%, on 472K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 291K | 472K | 61.7% | 2 |
| 2026-10-27 | 363K | 506K | 71.7% | 371 |
| 2026-10-26 | 350K | 487K | 71.8% | 20,302 |
| 2026-10-23 | 354K | 437K | 81.0% | 75 |
| 2026-10-22 | 343K | 475K | 72.2% | 945 |
| 2026-10-21 | 210K | 317K | 66.3% | 29 |
| 2026-10-20 | 330K | 459K | 71.9% | 53 |
| 2026-10-19 | 284K | 385K | 73.9% | 131 |
| 2026-10-16 | 184K | 288K | 63.9% | 10 |
| 2026-10-15 | 268K | 457K | 58.7% | 574 |
| 2026-10-14 | 248K | 472K | 52.5% | 4,551 |
| 2026-10-13 | 356K | 572K | 62.2% | 500 |
| 2026-10-12 | 175K | 264K | 66.1% | 0 |
| 2026-10-09 | 197K | 435K | 45.3% | 200 |
| 2026-10-08 | 297K | 563K | 52.7% | 0 |
| 2026-10-07 | 216K | 398K | 54.2% | 3,355 |
| 2026-10-06 | 383K | 494K | 77.4% | 5,428 |
| 2026-10-05 | 413K | 590K | 70.0% | 342 |
| 2026-10-02 | 453K | 611K | 74.2% | 0 |
| 2026-10-01 | 614K | 885K | 69.4% | 0 |
| 2026-09-30 | 460K | 616K | 74.7% | 340 |
| 2026-09-29 | 371K | 562K | 66.0% | 1,258 |
| 2026-09-28 | 397K | 646K | 61.5% | 1,240 |
| 2026-09-25 | 192K | 466K | 41.3% | 20 |
| 2026-09-24 | 315K | 448K | 70.3% | 165 |
| 2026-09-23 | 395K | 704K | 56.1% | 9 |
| 2026-09-22 | 251K | 460K | 54.4% | 11,528 |
| 2026-09-21 | 280K | 596K | 47.0% | 8 |
| 2026-09-18 | 359K | 461K | 78.0% | 127 |
| 2026-09-17 | 259K | 403K | 64.3% | 244 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 11 September 2026, the fails-to-deliver balance in NBIX is 1,221 shares, up 1,210 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (7 August 2026) to 228,282 shares (20 May 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-11 | 1,221 | $156.57 | $191K |
| 2026-09-09 | 11 | $155.13 | $2K |
| 2026-09-08 | 19 | $155.64 | $3K |
| 2026-08-28 | 1,609 | $155.92 | $251K |
| 2026-08-12 | 20 | $161.94 | $3K |
| 2026-08-07 | 1 | $159.82 | $160 |
| 2026-08-03 | 5,960 | $166.80 | $994K |
| 2026-07-29 | 33 | $182.83 | $6K |
| 2026-07-20 | 36 | $170.88 | $6K |
| 2026-07-09 | 382 | $178.24 | $68K |
| 2026-07-02 | 360 | $167.77 | $60K |
| 2026-06-25 | 201,605 | $166.06 | $33.5M |
| 2026-06-15 | 299 | $159.76 | $48K |
| 2026-06-08 | 246 | $163.88 | $40K |
| 2026-06-04 | 4,834 | $165.11 | $798K |
| 2026-06-02 | 28,872 | $161.00 | $4.6M |
| 2026-05-21 | 37,328 | $154.67 | $5.8M |
| 2026-05-20 | 228,282 | $154.36 | $35.2M |
| 2026-05-18 | 3,034 | $158.42 | $481K |
| 2026-05-15 | 3,224 | $159.05 | $513K |
| 2026-05-14 | 30,536 | $161.32 | $4.9M |
| 2026-05-13 | 28,599 | $155.80 | $4.5M |
| 2026-05-11 | 256 | $152.25 | $39K |
| 2026-05-07 | 11,883 | $147.02 | $1.7M |
| 2026-03-31 | 1,796 | $128.72 | $231K |
| 2026-03-23 | 2 | $127.68 | $255 |
| 2026-02-23 | 19,850 | $128.63 | $2.6M |
| 2026-02-04 | 696 | $138.98 | $97K |
| 2026-01-08 | 6,244 | $140.62 | $878K |
| 2025-12-22 | 4,323 | $145.00 | $627K |
Insider trades
SEC Form 4, newest first. JSONInsiders at NBIX reported 3 open-market sells worth $826K in the last 90 days and no open-market buys. Latest filing: Boyer David W. (Chief Corp. Affairs Officer) on 2026-09-14.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Boyer David W. | Chief Corp. Affairs Officer | Sell | 826 | $157.45 | $130K | 9K |
| 2026-09-14 | ABERNETHY MATT | Chief Financial Officer | Sell | 2K | $157.20 | $363K | 43K |
| 2026-09-11 | Onyia Jude | Chief Scientific Officer | Tax withholding | 2K | $156.22 | $302K | 23K |
| 2026-09-11 | Onyia Jude | Chief Scientific Officer | Grant | 4K | $0.00 | $0 | 25K |
| 2026-09-11 | Lippoldt Darin | Chief Legal Officer | Tax withholding | 2K | $156.22 | $378K | 57K |
| 2026-09-11 | Lippoldt Darin | Chief Legal Officer | Grant | 4K | $0.00 | $0 | 59K |
| 2026-09-11 | Keswani Sanjay Chandru | Chief Medical Officer | Tax withholding | 2K | $156.22 | $330K | 3K |
| 2026-09-11 | Keswani Sanjay Chandru | Chief Medical Officer | Grant | 4K | $0.00 | $0 | 5K |
| 2026-09-11 | Gano Kyle | Chief Executive Officer | Tax withholding | 994 | $156.22 | $155K | 155K |
| 2026-09-11 | Gano Kyle | Chief Executive Officer | Grant | 2K | $0.00 | $0 | 156K |
| 2026-09-11 | Gano Kyle | Chief Executive Officer | Tax withholding | 3K | $156.22 | $529K | 154K |
| 2026-09-11 | Gano Kyle | Chief Executive Officer | Grant | 6K | $0.00 | $0 | 157K |
| 2026-09-11 | GORMAN KEVIN CHARLES | Director | Tax withholding | 8K | $156.22 | $1.2M | 518K |
| 2026-09-11 | GORMAN KEVIN CHARLES | Director | Grant | 14K | $0.00 | $0 | 526K |
| 2026-09-11 | Delaet Ingrid | Chief Regulatory Officer | Tax withholding | 2K | $156.22 | $378K | 18K |
| 2026-09-11 | Delaet Ingrid | Chief Regulatory Officer | Grant | 4K | $0.00 | $0 | 21K |
| 2026-09-11 | Cooke Julie | Chief Human Resources Officer | Tax withholding | 2K | $156.22 | $302K | 24K |
| 2026-09-11 | Cooke Julie | Chief Human Resources Officer | Grant | 4K | $0.00 | $0 | 26K |
| 2026-09-11 | Boyer David W. | Chief Corp. Affairs Officer | Tax withholding | 2K | $156.22 | $302K | 10K |
| 2026-09-11 | Boyer David W. | Chief Corp. Affairs Officer | Grant | 4K | $0.00 | $0 | 11K |
| 2026-09-11 | BENEVICH ERIC | Chief Commercial Officer | Tax withholding | 3K | $156.22 | $529K | 67K |
| 2026-09-11 | BENEVICH ERIC | Chief Commercial Officer | Grant | 6K | $0.00 | $0 | 71K |
| 2026-09-11 | ABERNETHY MATT | Chief Financial Officer | Tax withholding | 3K | $156.22 | $423K | 45K |
| 2026-09-11 | ABERNETHY MATT | Chief Financial Officer | Grant | 5K | $0.00 | $0 | 48K |
| 2026-09-09 | BENEVICH ERIC | Chief Commercial Officer | Sell | 2K | $154.61 | $333K | 64K |
| 2026-09-09 | BENEVICH ERIC | Chief Commercial Officer | Exercise or conversion | 3K | $43.24 | $138K | 67K |
| 2026-09-02 | SHERWIN STEPHEN A | Director | Gift | 1K | $0.00 | $0 | 15K |
| 2026-08-04 | Onyia Jude | Chief Scientific Officer | Gift | 2K | $0.00 | $0 | 21K |
| 2026-07-29 | Norwalk Leslie V | Director | Exercise or conversion | 842 | $139.43 | $117K | 2K |
| 2026-07-28 | Norwalk Leslie V | Director | Sell | 1K | $182.01 | $228K | 2K |
| 2026-07-10 | Delaet Ingrid | Chief Regulatory Officer | Sell | 4K | $181.02 | $791K | 16K |
| 2026-07-10 | Delaet Ingrid | Chief Regulatory Officer | Exercise or conversion | 4K | $106.02 | $463K | 21K |
| 2026-07-09 | Lippoldt Darin | Chief Legal Officer | Sell | 10K | $179.60 | $1.8M | 55K |
| 2026-07-09 | Lippoldt Darin | Chief Legal Officer | Exercise or conversion | 10K | $81.49 | $815K | 65K |
| 2026-07-09 | Delaet Ingrid | Chief Regulatory Officer | Sell | 8K | $178.72 | $1.5M | 16K |
| 2026-07-09 | Delaet Ingrid | Chief Regulatory Officer | Exercise or conversion | 8K | $103.52 | $873K | 25K |
| 2026-07-08 | Delaet Ingrid | Chief Regulatory Officer | Sell | 3K | $178.54 | $489K | 16K |
| 2026-07-08 | Delaet Ingrid | Chief Regulatory Officer | Exercise or conversion | 3K | $103.52 | $283K | 19K |
| 2026-07-07 | Delaet Ingrid | Chief Regulatory Officer | Sell | 3K | $178.57 | $607K | 16K |
| 2026-07-07 | Delaet Ingrid | Chief Regulatory Officer | Exercise or conversion | 3K | $103.52 | $352K | 20K |
| 2026-06-29 | Lippoldt Darin | Chief Legal Officer | Sell | 8K | $170.03 | $1.4M | 55K |
| 2026-06-29 | Lippoldt Darin | Chief Legal Officer | Exercise or conversion | 8K | $81.49 | $661K | 63K |
| 2026-06-29 | Lippoldt Darin | Chief Legal Officer | Sell | 2K | $170.81 | $289K | 55K |
| 2026-06-29 | Lippoldt Darin | Chief Legal Officer | Exercise or conversion | 2K | $81.49 | $138K | 56K |
| 2026-06-26 | Lippoldt Darin | Chief Legal Officer | Sell | 200 | $169.57 | $34K | 55K |
| 2026-06-26 | Lippoldt Darin | Chief Legal Officer | Exercise or conversion | 200 | $81.49 | $16K | 55K |
| 2026-06-05 | Onyia Jude | Chief Scientific Officer | Gift | 2K | $0.00 | $0 | 23K |
| 2026-06-05 | SHERWIN STEPHEN A | Director | Sell | 2K | $167.31 | $308K | 16K |
| 2026-06-05 | SHERWIN STEPHEN A | Director | Sell | 6K | $166.56 | $971K | 18K |
| 2026-06-05 | SHERWIN STEPHEN A | Director | Sell | 7K | $165.79 | $1.1M | 24K |
| 2026-06-05 | SHERWIN STEPHEN A | Director | Sell | 3K | $164.44 | $419K | 30K |
| 2026-06-05 | SHERWIN STEPHEN A | Director | Sell | 8K | $163.81 | $1.3M | 33K |
| 2026-06-05 | SHERWIN STEPHEN A | Director | Exercise or conversion | 10K | $79.79 | $798K | 41K |
| 2026-06-05 | SHERWIN STEPHEN A | Director | Exercise or conversion | 15K | $53.64 | $805K | 31K |
| 2026-06-04 | Norwalk Leslie V | Director | Sell | 1K | $168.06 | $210K | 3K |
| 2026-06-02 | Keswani Sanjay Chandru | Chief Medical Officer | Tax withholding | 2K | $154.84 | $268K | 1K |
| 2026-06-02 | Keswani Sanjay Chandru | Chief Medical Officer | Exercise or conversion | 3K | $0.00 | $0 | 3K |
| 2026-06-02 | Cooke Julie | Chief Human Resources Officer | Sell | 4K | $158.59 | $558K | 22K |
| 2026-06-02 | Cooke Julie | Chief Human Resources Officer | Sell | 10K | $157.62 | $1.5M | 26K |
| 2026-06-02 | Cooke Julie | Chief Human Resources Officer | Sell | 4K | $156.77 | $661K | 35K |
| 2026-06-02 | Cooke Julie | Chief Human Resources Officer | Sell | 5K | $155.46 | $850K | 40K |
| 2026-06-02 | Cooke Julie | Chief Human Resources Officer | Sell | 14K | $154.83 | $2.2M | 45K |
| 2026-06-02 | Cooke Julie | Chief Human Resources Officer | Exercise or conversion | 25K | $81.49 | $2.0M | 59K |
| 2026-06-01 | Onyia Jude | Chief Scientific Officer | Sell | 11K | $160.25 | $1.8M | 26K |
| 2026-06-01 | Onyia Jude | Chief Scientific Officer | Exercise or conversion | 11K | $84.74 | $932K | 37K |
| 2026-05-29 | Delaet Ingrid | Chief Regulatory Officer | Sell | 2K | $156.71 | $354K | 16K |
| 2026-05-29 | Delaet Ingrid | Chief Regulatory Officer | Exercise or conversion | 2K | $79.02 | $179K | 18K |
| 2026-05-27 | Onyia Jude | Chief Scientific Officer | Sell | 11K | $155.53 | $1.7M | 26K |
| 2026-05-27 | Onyia Jude | Chief Scientific Officer | Exercise or conversion | 11K | $84.74 | $932K | 37K |
| 2026-05-26 | Boyer David W. | Chief Corp. Affairs Officer | Sell | 4K | $156.64 | $609K | 8K |
| 2026-05-21 | Norwalk Leslie V | Director | Exercise or conversion | 2K | $0.00 | $0 | 4K |
| 2026-05-21 | Sharp Shalini | Director | Exercise or conversion | 2K | $0.00 | $0 | 4K |
| 2026-05-21 | RASTETTER WILLIAM H | Director | Exercise or conversion | 3K | $0.00 | $0 | 44K |
| 2026-05-21 | POON CHRISTINE A | Director | Exercise or conversion | 3K | $0.00 | $0 | 5K |
| 2026-05-21 | POPS RICHARD F | Director | Exercise or conversion | 3K | $0.00 | $0 | 38K |
| 2026-05-21 | SHERWIN STEPHEN A | Director | Exercise or conversion | 3K | $0.00 | $0 | 16K |
| 2026-05-21 | Mercier Johanna | Director | Exercise or conversion | 3K | $0.00 | $0 | 7K |
| 2026-05-21 | MORROW GEORGE J | Director | Exercise or conversion | 3K | $0.00 | $0 | 10K |
| 2026-05-21 | LYONS GARY A | Director | Exercise or conversion | 2K | $0.00 | $0 | 122K |
| 2026-05-19 | GORMAN KEVIN CHARLES | Director | Sell | 245K | $154.33 | $37.8M | 511K |
| 2026-05-19 | GORMAN KEVIN CHARLES | Director | Exercise or conversion | 205K | $43.24 | $8.9M | 756K |
| 2026-05-15 | POPS RICHARD F | Director | Sell | 15K | $157.65 | $2.4M | 34K |
| 2026-05-15 | POPS RICHARD F | Director | Exercise or conversion | 15K | $47.89 | $718K | 49K |
| 2026-05-12 | Norwalk Leslie V | Director | Sell | 4K | $155.01 | $591K | 2K |
| 2026-03-04 | ABERNETHY MATT | Chief Financial Officer | Gift | 2K | $0.00 | $0 | 43K |
| 2026-02-20 | Onyia Jude | Chief Scientific Officer | Gift | 3K | $0.00 | $0 | 26K |
| 2026-02-13 | Onyia Jude | Chief Scientific Officer | Tax withholding | 11K | $124.12 | $1.3M | 29K |
| 2026-02-13 | Onyia Jude | Chief Scientific Officer | Grant | 20K | $0.00 | $0 | 40K |
| 2026-02-13 | Onyia Jude | Chief Scientific Officer | Tax withholding | 1K | $124.12 | $182K | 20K |
| 2026-02-13 | Onyia Jude | Chief Scientific Officer | Exercise or conversion | 3K | $0.00 | $0 | 21K |
| 2026-02-13 | Onyia Jude | Chief Scientific Officer | Tax withholding | 1K | $124.12 | $180K | 18K |
| 2026-02-13 | Onyia Jude | Chief Scientific Officer | Exercise or conversion | 3K | $0.00 | $0 | 20K |
| 2026-02-13 | Lippoldt Darin | Chief Legal Officer | Gift | 365 | $0.00 | $0 | 55K |
| 2026-02-13 | Lippoldt Darin | Chief Legal Officer | Tax withholding | 5K | $124.12 | $668K | 55K |
| 2026-02-13 | Lippoldt Darin | Chief Legal Officer | Grant | 10K | $0.00 | $0 | 60K |
| 2026-02-13 | Lippoldt Darin | Chief Legal Officer | Tax withholding | 1K | $124.12 | $140K | 51K |
| 2026-02-13 | Lippoldt Darin | Chief Legal Officer | Exercise or conversion | 2K | $0.00 | $0 | 52K |
| 2026-02-13 | Lippoldt Darin | Chief Legal Officer | Tax withholding | 1K | $124.12 | $135K | 50K |
| 2026-02-13 | Lippoldt Darin | Chief Legal Officer | Exercise or conversion | 2K | $0.00 | $0 | 51K |
| 2026-02-13 | Gano Kyle | Chief Executive Officer | Tax withholding | 5K | $124.12 | $668K | 151K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON25 Form 144 notices on file for NBIX worth $79.9M at the prices reported; 3 in the last 90 days worth $1.4M. Latest: DAVID WARREN BOYER filed on 2026-09-14 to sell 4,714 shares ($736K) from 2026-09-14.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-14 | DAVID WARREN BOYEROfficer | 5K | $736K | 0.005% | 2026-09-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-14 | MATTHEW C ABERNETHYOfficer | 2K | $361K | 0.002% | 2026-09-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-09 | ERIC BENEVICHOfficer | 2K | $334K | 0.002% | 2026-09-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-10 | INGRID DELAETOfficer | 4K | $788K | 0.004% | 2026-07-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-09 | DARIN LIPPOLDTOfficer | 10K | $1.8M | 0.010% | 2026-07-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-07 | INGRID DELAETOfficer | 15K | $2.5M | 0.014% | 2026-07-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-29 | DARIN LIPPOLDTOfficer | 10K | $1.7M | 0.010% | 2026-06-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-26 | DARIN LIPPOLDTOfficer | 200 | $33K | 0.000% | 2026-06-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-05 | STEPHEN SHERWINDirector | 25K | $4.2M | 0.025% | 2026-06-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-02 | JULIE COOKEOfficer | 37K | $5.9M | 0.037% | 2026-06-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-01 | JUDE ONYIAOfficer | 11K | $1.7M | 0.011% | 2026-06-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-29 | INGRID DELAETOfficer | 2K | $354K | 0.002% | 2026-05-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-27 | JUDE ONYIAOfficer | 11K | $1.7M | 0.011% | 2026-05-27 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-26 | DAVID WARREN BOYEROfficer | 4K | $609K | 0.004% | 2026-05-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-19 | KEVIN CHARLES GORMANDirector | 245K | $38.5M | 0.244% | 2026-05-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-15 | RICHARD F POPSDirector | 15K | $2.4M | 0.015% | 2026-05-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-12 | Norwalk Leslie VDirector | 6K | $1.0M | 0.006% | 2026-05-12 | THE CHARLES SCHWAB CORPORATION |
| 2026-01-16 | KYLE GANOOfficer | 36K | $4.9M | 0.037% | 2026-01-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-15 | Norwalk Leslie VDirector | 11K | $1.7M | 0.011% | 2025-12-15 | THE CHARLES SCHWAB CORPORATION |
| 2025-12-08 | DARIN LIPPOLDTOfficer | 4K | $681K | 0.004% | 2025-12-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-03 | GARY A LYONS REVOCABLE LIVING U/A DTD 06/08/2012Director | 15K | $2.3M | 0.015% | 2025-12-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-28 | ERIC BENEVICHOfficer | 6K | $905K | 0.006% | 2025-11-28 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-25 | GEORGE MORROWDirector | 15K | $2.1M | 0.015% | 2025-11-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-05 | WILLIAM H. RASTETTERDirector | 18K | $2.6M | 0.018% | 2025-11-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-05 | Gano KyleOfficer, Director | 300 | $43K | 0.000% | 2025-11-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON2 holders report 5% or more of NBIX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Vanguard Capital Management at 5.2% of the class (5,257,941 shares), filed 2026-04-30 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-15 | 13G/Ano. 2 | JPMORGAN CHASE & CO.parent holding company | 5.3M | 5.2% | 2026-09-30 |
| 2026-04-30 | 13G | Vanguard Capital Managementinvestment adviser | 5.3M | 5.2% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 10 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding NBIX at their latest 13F. JSON8 of the 30 tracked managers held NBIX at their latest 13F, $1.45B in total at quarter-end prices. AQR Capital Management is the largest at $643.5M (0.2% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 6 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 3.8M | $643.5M | 0.22% | -1.1M |
| Renaissance Technologies | 2026-06-30 | 2.3M | $393.7M | 0.54% | -83K |
| Two Sigma Investments | 2026-06-30 | 2.1M | $349.9M | 0.25% | -984K |
| Bridgewater Associates | 2026-06-30 | 206K | $34.7M | 0.14% | +58K |
| Fisher Asset Management | 2026-06-30 | 135K | $22.8M | 0.01% | +13K |
| Citadel Advisors | 2026-06-30 | 12K | $2.0M | 0.00% | -46K |
| Millennium Management | 2026-06-30 | 12K | $2.0M | 0.00% | -1.2M |
| D. E. Shaw & Co. | 2026-06-30 | 6K | $944K | 0.00% | -84K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Neurocrine Biosciences reported revenue of $959.0M, up 39.5% from the same quarter a year earlier, and net income of $144.4M (1.39 diluted EPS). In FY 2025 it generated $782.7M of operating cash flow and spent $167.7M on buybacks.
- Cash
- $332.4M
- Equity
- $3.69B
- Total assets
- $5.36B
- Shares outstanding
- 101,649,181
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $959.0M | $144.4M | 15.1% | 1.39 |
| Q1 FY 2026 | 2026-03-31 | $814.5M | $197.9M | 24.3% | 1.91 |
| Q4 FY 2025derived | 2025-12-31 | $805.5M | $153.7M | 19.1% | n/a |
| Q3 FY 2025 | 2025-09-30 | $794.9M | $209.5M | 26.4% | 2.04 |
| Q2 FY 2025 | 2025-06-30 | $687.5M | $107.5M | 15.6% | 1.06 |
| Q1 FY 2025 | 2025-03-31 | $572.6M | $7.9M | 1.4% | 0.08 |
| Q4 FY 2024derived | 2024-12-31 | $627.7M | $103.1M | 16.4% | n/a |
| Q3 FY 2024 | 2024-09-30 | $622.1M | $129.8M | 20.9% | 1.24 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $2.86B | $478.6M | $782.7M | $34.0M | $167.7M | n/a |
| FY 2024 | 2024-12-31 | $2.36B | $341.3M | $595.4M | $38.2M | $300.0M | n/a |
| FY 2023 | 2023-12-31 | $1.89B | $249.7M | $389.9M | $28.3M | $0 | n/a |
| FY 2022 | 2022-12-31 | $1.49B | $154.5M | $339.4M | $16.5M | $0 | n/a |
| FY 2021 | 2021-12-31 | $1.13B | $89.6M | $256.5M | $23.4M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-22 from the cover page.
What this page is
Neurocrine Biosciences in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Neurocrine Biosciences (NBIX), SEC CIK 914475, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-11.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-14.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-15.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-07-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-14.JSON and CSV
- Company record
- EDGAR filing index for CIK 914475Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
Datasets
Frequently Asked Questions
How much of NBIX is sold short?
6,447,491 shares were held short at the 2026-10-15 settlement, 4.5 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is NBIX's daily short volume?
On 2026-10-28, 291,326 of the 472,349 NBIX shares reported to FINRA were sold short, 61.7% of the day's reported volume. Short volume is a flow for one day, not a position.
Does NBIX have fails to deliver?
The SEC's latest file shows 1,221 NBIX shares failed to deliver at settlement 2026-09-11. Fails are reported per settlement date and published twice a month with a lag.
Are NBIX insiders buying or selling?
Insiders at NBIX reported 3 open-market sells worth $826K in the last 90 days and no open-market buys. Latest filing: Boyer David W. (Chief Corp. Affairs Officer) on 2026-09-14.
Have NBIX insiders filed to sell?
25 Form 144 notices on file for NBIX worth $79.9M at the prices reported; 3 in the last 90 days worth $1.4M. Latest: DAVID WARREN BOYER filed on 2026-09-14 to sell 4,714 shares ($736K) from 2026-09-14.
Who owns 5% or more of NBIX?
2 holders report 5% or more of NBIX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Vanguard Capital Management at 5.2% of the class (5,257,941 shares), filed 2026-04-30 for an event on 2026-03-31.
What did NBIX report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Neurocrine Biosciences reported revenue of $959.0M, up 39.5% from the same quarter a year earlier, and net income of $144.4M (1.39 diluted EPS). In FY 2025 it generated $782.7M of operating cash flow and spent $167.7M on buybacks.
Which tracked 13F managers own NBIX?
8 of the 30 tracked 13F managers held NBIX shares at their latest filing, $1.45B in all. The largest: Cliff Asness's AQR Capital Management (3.8M shares, $643.5M), Renaissance Technologies (2.3M shares, $393.7M), Two Sigma Investments (2.1M shares, $349.9M), Ray Dalio's Bridgewater Associates (206K shares, $34.7M), Ken Fisher's Fisher Asset Management (135K shares, $22.8M), Ken Griffin's Citadel Advisors (12K shares, $2.0M). The table above lists all 8.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.